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Selective internal radiation therapy (SIRT) using 90-yttrium is a local therapy for unresectable liver malignancies.
Non-targeted 90-yttrium diversion via a patent hepatic falciform artery (HFA) is seen as risk for periprocedural
complications. Therefore, this study aimed to evaluate the impact of a patent HFA on SIRT. 606 patients with
SIRT between 2006 and 2012 were evaluated retrospectively. SIRT preparation was performed by digital subtraction
angiography including 99mTc-HSAM administration and subsequent SPECT/CT. Patients with an angiographically patent
HFA were analyzed for procedural consequences and complications. 19 of 606 patients (3%) with an angiographically
patent HFA were identified. Only 11 of these 19 patients received 90-yttrium in the hepatic vessel bed containing the
HFA. Initial coil embolization of the HFA succeeded only in three of 11 patients. Out of the eight remaining
patients four had no abdominal wall 99mTc-HSAM accumulation. The other four patients presented with an abdominal
wall 99mTc-HSAM accumulation, for those a reattempt of HFA embolization was performed or ice packs were administered
on the abdominal wall during SIRT. In summary, all patients tolerated SIRT well. A patent HFA should not be considered a
SIRT contraindication. In patients with abdominal wall 99mTc-HSAM accumulation HFA embolization or ice pack
administration seems to prevent complications.
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Selective internal radiation therapy (SIRT) using 90-yttrium
microspheres is increasingly used as a treatment option for
unresectable primary and secondary liver malignancies
(Salem and Thurston 2006a, b, c; Salem et al. 2005, 2007;
Lewandowski et al. 2007; Powerski et al. 2012; Wybranski
et al. 2009; Dudeck et al. 2010). Due to the mainly arterial
blood supply of the tumor, but the dual arterial and
portal-venous blood supply of the liver, the intraarter-
ial application of the pure β-emitter 90-yttrium allows
the administration of a high radiation dosage into the
tumor with partially sparing the healthy liver tissue. To
achieve the required therapeutic radiation dosage in
the tumor, approximately 1.0 - 3.0 GBq have to be* Correspondence: juliane.schelhorn@uk-essen.de
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in any medium, provided the original work is papplied (Salem and Thurston 2006a; Wybranski et al.
2009; Grober et al. 2011). Respectively the non-targeted
diversion of 90-yttrium microspheres to other organs may
lead to severe complications such as radiation gastritis,
gastrointestinal ulcers, pancreatitis, and pneumonitis
(Salem and Thurston 2006b; Paprottka et al. 2012;
Pech et al. 2009; Dudeck et al. 2011). Less dangerous,
nevertheless compromising, self-limiting periumbilical
radiation dermatitis and severe periumbilical pain due
to non-targeted diversion of 90-yttrium microspheres
to the anterior abdominal wall via a patent hepatic fal-
ciform artery (HFA) have been reported (Leong et al.
2009; Bhalani and Lewandowski 2011). Hence, the aim
of this study was to evaluate the frequency and the im-
pact of an angiographically patent HFA in SIRT and to
assess strategies to reduce concomitant complications.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Patients
Retrospective analysis and use of data was approved by the
local ethics committee (ethics committee of the University
Essen). All 606 patients (464 male, 142 female, mean age
64.5 years) who underwent SIRT between October 2006
and December 2012 at our hospital were reevaluated with
respect to an angiographically detectable patent HFA. All
patients were not eligible for curative treatment due to their
advanced tumor disease. The tumor entities were hepatocel-
lular carcinoma (n = 476), cholangiocarcinoma (n = 14),
and hepatic metastases (n = 116). Cirrhotic patients with
Child Pugh score >7 points were not eligible for SIRT.
Digital subtraction angiography (DSA)
DSA was performed on a biplanar DSA system (Philips
Allura, Philips Healthcare, Best, The Netherlands; or
Toshiba Infinix DP-i, Toshiba Medical Systems, Tokyo,
Japan). Using Seldinger technique a 5 F vascular sheath
(Avanti + Sheath Introducer, Cordis Europe, Waterloo,
Belgium) and a 5 F guiding catheter (Sidewinder-1,
Sindwinder-2 or Cobra-2; Terumo Europe, Leuven,
Belgium) were inserted via a transfermoral access. Se-
lective DSA of the celiac trunk and the superior mes-
enteric artery was performed with 15 ml of contrast
agent (Xenetix, Guerbet, Roissy, France) at a flow rate
of 5 ml/s by an automatic injector (Tyco Healthcare,
Mansfield, MA, USA). Imaging parameters were 80 kV, 70
mAs, and 2 images/s. After visualization of the tumor ex-
tent an appropriate microcatheter (Rebar 0.27 inch, ev3
Europe SAS, Paris, France) position for the 99mTc-HSAM
(99 m-technetium labelled human serum albumin micro-
spheres, ROTOP Pharmaka AG, Dresden, Germany) ad-
ministration was defined for the right, left, or both hepatic
lobes. If the gastroduodenal artery or the right gastric ar-
tery were identified near the intended injection site, they
were occluded by permanent coil embolization using
interlocking detachable or pushable coils (Boston Scien-
tific, Natick, MA, USA or Cook Medical, Bloomington,
IN, USA; microcatheters for coiling: Rebar 0.18 inch, ev3
Europe SAS, Paris, France or Renegade 21, Boston Scien-
tific, Natick, MA, USA). A patent HFA in DSA was
attempted to probe and coil embolize. Finally, a total
of 150 MBq 99mTc-HSAM was injected at the defined
microcatheter positions.
Single-photon emission computed tomography/computed
tomography (SPECT/CT)
SPECT/CT images were acquired using a Symbia SPECT/
CT system (Siemens Healthcare, Erlangen, Germany)
60 minutes after 99mTc-HSAM administration. Unen-
hanced low dose computed tomography was acquired
at 128 kV and 17 mAs and reconstructed with 5 mm
slice thickness. For SPECT 128 frames (25 s/frame)were collected with a 128 × 128 matrix and attenuation
and scatter slices were reconstructed iteratively. The fu-
sion images were computed via e.soft 2007 application
package (Siemens Healthcare, Erlangen, Germany). In the
subsequent qualitative visual analysis any noticeable tracer
accumulation in the anterior abdominal wall or in the fal-
ciform ligament was registered. In cases with an apparent
tracer uptake in these locations strategies to reduce the
risk for non-targeted 90-yttrium diversion to the abdom-
inal wall were evaluated.
Selective internal radiation therapy using 90-yttrium
(SIRT)
90-yttrium administration (TheraSphere™, BTG, Hertford-
shire, United Kingdom) was performed on an average of
45 days after the initial DSA (range: 16 – 86 days). The
therapeutic DSA was performed in the same way as the
pretherapeutic DSA using the same equipment. Patients
whose HFA could primarily not be occluded but who did
not present with any 99mTc-HSAM accumulation in the
anterior abdominal wall or in the falciform ligament, re-
ceived SIRT without any special precautions. In patients,
whose HFA could primarily not be coil embolized and
who presented with a 99mTc-HSAM accumulation in the
anterior abdominal wall or in the falciform ligament, a re-
attempt of probing and transient occlusion of the HFA
with gelfoam (Gelitaspon, Gelita Medical, Amsterdam,
The Netherlands) was performed. If probing and oc-
clusion of the HFA was not feasible, ice packs were ad-
ministered on the ventral mid abdominal wall prior to
90-yttrium administration.
Follow up
All patients stayed for 48 hours after 90-yttrium adminis-
tration as inpatients and were monitored for any adverse
event especially acute radiation dermatitis, periumbilical
skin rash, or abdominal pain. Furthermore, the patients
had been instructed to contact the hospital in case of any
adverse event after their discharge.
Results
In 19 of 606 patients (3%) a patent HFA was detected by
DSA; however in 48 patients (8%) a slight 99mTc-HSAM
accumulation in the ventral abdominal wall was found
but no HFA was detected. In 18 of the 19 patients with
angiographically patent HFA it arose from a branch of
the left hepatic artery. Only in one patient it originated
from a branch of the right hepatic artery.
Eight of these 19 patients did not receive 90-yttrium in
the hepatic vessel bed containing the HFA due to clinical
deterioration (n = 4), persistent duodenal shunting (n = 1),
insufficient tumor 99mTc-HSAM accumulation (n = 1), or
because the liver tumor was located exclusively in the
contralateral liver lobe (n = 2). Hence, only 11 patients
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HFA arose. In three of these 11 patients the HFA could ini-
tially be coil embolized. None of these patients showed
any 99mTc-HSAM accumulation in the ventral abdominal
wall or the falciform ligament (Figure 1A-C). In two of
these three patients a partial reopening of the HFA was
discovered during subsequent therapeutic DSA. Thus, the
HFA was reoccluded with gelfoam prior to the 90-yttrium
administration (Figure 2A-D). All three patients tolerated
SIRT well without any complications.
In eight out of these 11 patients the HFA could not be
occluded primarily. Four of these eight patients did nei-
ther exhibit any 99mTc-HSAM accumulation in the an-
terior abdominal wall nor in the falciform ligament in
subsequent SPECT/CT. Consequently, the flow in the
HFA was regarded as non-significant and therefore these
four patients received SIRT without any special precau-
tions. All four patients tolerated SIRT well. The remaining
four patients with a persistently patent HFA presented
with a 99mTc-HSAM uptake in the anterior abdominal
wall (n = 3) or in the falciform ligament (n = 1). Hence, a
reattempt of HFA occlusion with gelfoam was performed
in all four patients, but succeeded only in two of them.
These two patients received SIRT without any complica-
tions. In the remaining two patients the HFA was persist-
ently not probable, so ice packs were placed on the anterior
mid abdominal wall of these patients during 90-yttrium ad-
ministration (Figure 3A-C) aiming on vasoconstriction of
the cutaneous vessels and a consecutive flow reduction in
the HFA. Both patients received SIRTand tolerated it well.
Discussion
This retrospective study points out two main messages:
First, an angiographically patent HFA is only detected in a
small percentage (3%) of patients undergoing SIRT. Sec-
ondly, according to our experience, a patent HFA is not a
contraindication for SIRT, especially if certain precautions
such as coil embolization of the HFA or ice pack adminis-
tration on the ventral mid abdominal wall are carried out.Figure 1 Example of a coilable hepatic falciform artery (HFA). Primarily
successfully coil embolized (B). Afterwards no abdominal wall 99mTc-HSAMInadvertent distribution of 90-yttrium to the ventral
abdominal wall via a patent HFA has been described as a
complication of SIRT which may result in acute radiation
dermatitis, periumbilical skin rash, or severe mid abdom-
inal pain (Leong et al. 2009; Bhalani and Lewandowski
2011). For protective reasons, in cases of a patent HFA
a pretherapeutic occlusion of the HFA or a superselec-
tive SIRT sparing the HFA dispensing vessel have been
proposed (Bhalani and Lewandowski 2011; Kao et al.
2011; Haggerty et al. 2012). But recently, Wang et al.
(2013) reported on radioembolization in five patients
with a patent HFA. Like in our two patients with per-
sistently not probable HFA, Wang et al. did not oc-
clude the HFA but solely placed ice packs on the
ventral mid abdominal wall and experienced no com-
plications in all five patients.
In the current cohort, a patent HFA was found only in
3% of all patients. This is in accordance with results of a
large study cohort in which HFA was seen in 2% of 1250
patients (Baba et al. 2000). An even smaller prevalence
of an angiographically patent HFA (0.5%) was reported
by Ahmadzadehfar et al. (2011) who investigated 192 pa-
tients. They found a 99mTc-HSAM accumulation in the
anterior abdominal wall in 9% of patients, which is com-
parable to the currently reported 8%. Ahmadzadehfar
et al. occluded the sole angiographically detected patent
HFA. In the remaining patients with 99mTc-HSAM accu-
mulation in the anterior abdominal wall they performed
radioembolization without any modifications in the
treatment plan regarding the HFA and reported self-
limiting abdominal muscle pain in only one patient as a
possible symptom of a radiation induced complication.
However, although only minor adverse events were re-
ported in this study, we suggest protective procedures
such as embolization of the HFA or ice pack administra-
tion on the ventral abdominal wall prior to 90-yttrium
administration. Thus, the (mainly small) risk of side ef-
fects due to microsphere diversion to the abdominal wall
may be reduced.patent HFA visible in the pretherapeutic DSA (A) which was
acculumulation was detected in the SPECT/CT (C).
Figure 2 Example of a coilable, but subsequently partially recanalized hepatic falciform artery (HFA). Patent HFA visible in the DSA
(A) which initially was coil embolized (B) but which proofed partially recanalized in the therapeutic DSA (C). Subsequently it was reoccluded
using gelfoam (D) prior to the 90-yttrium administration.
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tients exhibited a patent HFA in DSA. Interestingly the
HFA could be identified in 52% of their patients by com-
puted tomography hepatic arteriography (CTHA) with
transcatheteral contrast agent administration in the hep-
atic arteries. The visualization of the HFA in DSA is af-
fected not only by the size of the vessel but also by
balancing of blood pressure between the HFA and the
internal mammary artery. The reported high HFA detec-
tion rate in CTHA may be due to the common diminu-
tive size of the HFA that leads to just a remote blood
flow in the vessel resulting in a higher HFA detection
rate in the more sensitive CTHA compared to conven-
tional DSA. However, the implications for the clinical
routine are questionable. A direct coil embolization in
these minute vessels seems to be not always feasible as
their study showed as well (Burgmans et al. 2012). A coil
embolization was possible only in two of 22 patients
with patent HFA detected by CTHA. The remaining 20
patients received SIRT without further precautions and
SIRT was tolerated well by all. This leads to the conclu-
sion that the higher sensitivity of CTHA does not mod-
ify the clinical practice because a diminutive HFA with a
negligible blood flow is probably not prone to cause
SIRT complications. Only the presence of a HFA with aFigure 3 Example of a not coilable hepatic falciform artery (HFA). Pat
the SPECT/CT an abdominal wall 99mTc-HSAM acculumulation was detecte
abdominal wall prior to 90-yttrium administration (C) which was finally tolelarger diameter, which can be detected by DSA or
SPECT/CT, should lead to clinical consequences as
discussed above.
Despite the high number of SIRT procedures per-
formed at our hospital between October 2006 and De-
cember 2012 we have never experienced acute radiation
dermatitis, periumbilical rash, or midabdominal pain
due to unintentional distribution of 90-yttrium via a
patent HFA. To reduce all potential risks we prophy-
lactically embolized the HFA if possible. Nevertheless,
patients whose HFA could not be occluded never experi-
enced any SIRT complications. Particularly, in patients
with a patent HFA but without any 99mTc-HSAM accu-
mulation in the anterior abdominal wall SIRT is safe. But
even in subjects with 99mTc-HSAM uptake in the anterior
abdominal wall and a non coilable HFA SIRT seems to be
feasible. In these patients we suggest administration of ice
packs on the anterior abdominal wall aiming for a
temperature induced vessel constriction and a con-
secutively reduced HFA flow.
Our study is not without limitations. First and fore-
most, the diagnostic DSA were performed by different
interventional radiologists. However, the procedures to
prepare for SIRT are highly standardized at our institu-
tion and all images were reanalyzed for this study.ent HFA detectable in DSA (A) which could not be coil embolized. In
d (B), hence to prevent SIRT sequela ice packs were placed on the
rated well.
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would be favorable to perform a prospective trial com-
paring the outcome of two patient groups with and with-
out safety precautions prior to SIRT. However, due to
the infrequence of a patent HFA this would have been
challenging.
Overall, our data underline the low complication rate
of SIRT if specific precautions are considered. Therefore
a patent HFA should not be regarded as an absolute or
even relative contraindication for SIRT.
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